The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

In April 2025, Terns enrolled the first patient in the dose expansion portion of the Phase 1 CARDINAL study of TERN-701 for CML. Patients will be randomized to one of two dose cohorts (320 mg or 500 ...